Literature DB >> 31537529

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.

Mounica Vallurupalli, Nancy Berliner.   

Abstract

Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against interferon-γ (IFN-γ), which in November 2018 received the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to HLH therapy. This review will highlight the pathophysiology of primary HLH, the therapeutic rationale for use of IFN-γ-targeting therapy, and potential limitations to its broader use in the treatment of HLH.
© 2019 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31537529      PMCID： PMC8938935          DOI： 10.1182/blood.2019002289

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  22 in total

1.  Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions.

Authors:  Eiichi Ishii; Ikuyo Ueda; Ryutaro Shirakawa; Ken Yamamoto; Hisanori Horiuchi; Shouichi Ohga; Kenji Furuno; Akira Morimoto; Miyoko Imayoshi; Yoshiyasu Ogata; Masafumi Zaitsu; Masahiro Sako; Kenichi Koike; Akifumi Sakata; Hidetoshi Takada; Toshiro Hara; Shinsaku Imashuku; Takehiko Sasazuki; Masaki Yasukawa
Journal:  Blood       Date:  2005-01-04       Impact factor: 22.113

Review 2.  Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Authors:  Jean-François Emile; Oussama Abla; Sylvie Fraitag; Annacarin Horne; Julien Haroche; Jean Donadieu; Luis Requena-Caballero; Michael B Jordan; Omar Abdel-Wahab; Carl E Allen; Frédéric Charlotte; Eli L Diamond; R Maarten Egeler; Alain Fischer; Juana Gil Herrera; Jan-Inge Henter; Filip Janku; Miriam Merad; Jennifer Picarsic; Carlos Rodriguez-Galindo; Barret J Rollins; Abdellatif Tazi; Robert Vassallo; Lawrence M Weiss
Journal:  Blood       Date:  2016-03-10       Impact factor: 22.113

3.  Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.

Authors:  Sabrin Albeituni; Katherine C Verbist; Paige E Tedrick; Heather Tillman; Jennifer Picarsic; Rachel Bassett; Kim E Nichols
Journal:  Blood       Date:  2019-04-23       Impact factor: 22.113

4.  Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.

Authors:  Jan-Inge Henter; AnnaCarin Samuelsson-Horne; Maurizio Aricò; R Maarten Egeler; Göran Elinder; Alexandra H Filipovich; Helmut Gadner; Shinsaku Imashuku; Diane Komp; Stephan Ladisch; David Webb; Gritta Janka
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

Review 5.  Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis.

Authors:  Carl E Allen; Kenneth L McClain
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

6.  An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder.

Authors:  Michael B Jordan; David Hildeman; John Kappler; Philippa Marrack
Journal:  Blood       Date:  2004-04-06       Impact factor: 22.113

7.  Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.

Authors:  Rupali Das; Peng Guan; Leslee Sprague; Katherine Verbist; Paige Tedrick; Qi Angel An; Cheng Cheng; Makoto Kurachi; Ross Levine; E John Wherry; Scott W Canna; Edward M Behrens; Kim E Nichols
Journal:  Blood       Date:  2016-01-29       Impact factor: 22.113

Review 8.  Emapalumab: First Global Approval.

Authors:  Zaina T Al-Salama
Journal:  Drugs       Date:  2019-01       Impact factor: 11.431

9.  Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+ T cells in persistent infection with lymphocytic choriomeningitis virus.

Authors:  D Binder; M F van den Broek; D Kägi; H Bluethmann; J Fehr; H Hengartner; R M Zinkernagel
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

Review 10.  Familial hemophagocytic lymphohistiocytosis: when rare diseases shed light on immune system functioning.

Authors:  Elena Sieni; Valentina Cetica; Yvonne Hackmann; Maria Luisa Coniglio; Martina Da Ros; Benedetta Ciambotti; Daniela Pende; Gillian Griffiths; Maurizio Aricò
Journal:  Front Immunol       Date:  2014-04-16       Impact factor: 7.561
View more
  37 in total

1.  Line-selective macrophage activation with an anti-CD40 antibody drives a hemophagocytic syndrome in mice.

Authors:  Giada Ingoglia; Ayla Yalamanoglu; Marc Pfefferlé; Irina L Dubach; Christian A Schaer; Kristyna Valkova; Kerstin Hansen; Nadja Schulthess; Rok Humar; Dominik J Schaer; Florence Vallelian
Journal:  Blood Adv       Date:  2020-06-23

2.  Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis.

Authors:  Matthias Felber; Colin G Steward; Karim Kentouche; Anders Fasth; Robert F Wynn; Ulrike Zeilhofer; Veronika Haunerdinger; Benjamin Volkmer; Seraina Prader; Bernd Gruhn; Stephan Ehl; Kai Lehmberg; Daniel Müller; Andrew R Gennery; Michael H Albert; Fabian Hauck; Kanchan Rao; Paul Veys; Moustapha Hassan; Arjan C Lankester; Jana Pachlopnik Schmid; Mathias M Hauri-Hohl; Tayfun Güngör
Journal:  Blood Adv       Date:  2020-05-12

Review 3.  Haemophagocytic lymphohistiocytosis in pregnancy.

Authors:  Harold Wilson-Morkeh; Charlotte Frise; Taryn Youngstein
Journal:  Obstet Med       Date:  2021-09-26

Review 4.  Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis.

Authors:  Han-Qi Zhang; Si-Wei Yang; Yi-Cheng Fu; Ming-Cong Chen; Cheng-Hao Yang; Ming-Hua Yang; Xiao-Dan Liu; Qing-Nan He; Hua Jiang; Ming-Yi Zhao
Journal:  Immunol Res       Date:  2022-07-11       Impact factor: 4.505

5.  Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.

Authors:  Ran Wang; Ting Li; Shuang Ye; Liangjin Lv; Sheng Chen; Xiaodong Wang; Chun-de Bao; Qiong Fu
Journal:  Clin Rheumatol       Date:  2022-05-19       Impact factor: 3.650

Review 6.  JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.

Authors:  Yiming Luo; Madison Alexander; Massimo Gadina; John J O'Shea; Francoise Meylan; Daniella M Schwartz
Journal:  J Allergy Clin Immunol       Date:  2021-10       Impact factor: 14.290

Review 7.  The amount of cytokine-release defines different shades of Sars-Cov2 infection.

Authors:  S Bindoli; M Felicetti; P Sfriso; A Doria
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-28

Review 8.  Infection-induced inflammation from specific inborn errors of immunity to COVID-19.

Authors:  Cheng-Lung Ku; I-Ting Chen; Ming-Zong Lai
Journal:  FEBS J       Date:  2021-05-20       Impact factor: 5.622

Review 9.  The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders.

Authors:  Danielle E Arnold; Deepak Chellapandian; Jennifer W Leiding
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

10.  Novel XIAP mutation causing enhanced spontaneous apoptosis and disturbed NOD2 signalling in a patient with atypical adult-onset Crohn's disease.

Authors:  Zuzana Parackova; Tomas Milota; Petra Vrabcova; Jitka Smetanova; Michael Svaton; Tomas Freiberger; Veronika Kanderova; Anna Sediva
Journal:  Cell Death Dis       Date:  2020-06-08       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.